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BRIEF DEFINITIVE REPORT
SARM1 deﬁciency up-regulates XAF1, promotes
neuronal apoptosis, and accelerates prion disease
Caihong Zhu*, Bei Li*, Karl Frontzek, Yingjun Liu, and Adriano Aguzzi
SARM1 (sterile α and HEAT/armadillo motif–containing protein) is a member of the MyD88 (myeloid differentiation primary
response gene 88) family, which mediates innate immune responses. Because inactivation of SARM1 prevents various forms of
axonal degeneration, we tested whether it might protect against prion-induced neurotoxicity. Instead, we found that SARM1
deﬁciency exacerbates the progression of prion pathogenesis. This deleterious effect was not due to SARM1-dependent
modulation of prion-induced neuroinﬂammation, since microglial activation, astrogliosis, and brain cytokine proﬁles were not
altered by SARM1 deﬁciency. Whole-transcriptome analyses indicated that SARM1 deﬁciency led to strong, selective
overexpression of the pro-apoptotic gene XAF1 (X-linked inhibitor of apoptosis-associated factor 1). Consequently, the activity
of pro-apoptotic caspases and neuronal death were enhanced in prion-infected SARM1−/− mice. These results point to an
unexpected function of SARM1 as a regulator of prion-induced neurodegeneration and suggest that XAF1 might constitute a
therapeutic target in prion disease.
Introduction
SARM1 (sterile α and HEAT/armadillo motif–containing pro-
tein), a member of MyD88 (myeloid differentiation primary
response gene 88) family (MyD88-5), is a highly conserved cy-
tosolic adaptor molecule that negatively regulates TRIF (Toll/
interleukin-1 receptor [TIR] domain–containing adaptor induc-
ing interferon-β)-mediated TLR signaling in mammalian cell
cultures (Carty et al., 2006). SARM1 is expressed primarily by
neurons in the mouse brain (Kim et al., 2007). By decreasing the
association of JNK3 with mitochondria, SARM1 deﬁciency pro-
tects neurons from death due to oxygen and glucose deprivation
(Kim et al., 2007). Similarly, SARM1−/−mice also show protection
from neuronal injury induced by vesicular stomatitis virus and
La Crosse virus (Hou et al., 2013; Mukherjee et al., 2013). On the
other hand, SARM1 restricts neurotropic West Nile virus
(WNV) infection by modulating microglia activation and cyto-
kine production (Szretter et al., 2009). These studies suggest
an involvement of SARM1-mediated innate immunity in neu-
ronal death.
Two independent genetic screens identiﬁed SARM1 as a
mediator of Wallerian axonal degeneration after acute nerve
injury (Osterloh et al., 2012; Gerdts et al., 2013). SARM1 triggers
Wallerian degeneration by activating the MAPK cascade,
through nicotinamide adenine dinucleotide (NAD+) depletion
(Gerdts et al., 2015, 2016; Yang et al., 2015; Sasaki et al., 2016;
Essuman et al., 2017; Walker et al., 2017) and by stimulating Ca2+
inﬂux into injured axons (Loreto et al., 2015). In addition,
SARM1 mediates axon degeneration in traumatic brain injury
and vincristine-induced peripheral neuropathy (Geisler et al.,
2016; Henninger et al., 2016). These ﬁndings raise the question
of whether SARM1 might participate to further neurodegener-
ative pathologies.
Prion diseases are a group of neurodegenerative disorders
characterized by the deposition of PrPSc, a misfolded isoform of
cellular prion protein (PrPC), in the central nervous system and
other organs (Aguzzi and Zhu, 2012). Progressive accumulation
of PrPSc in the central nervous system leads to lethal encepha-
lopathies associated with neuronal loss, spongiform change, and
neuroinﬂammation (Aguzzi et al., 2013). The contribution of
innate immunity to prion pathogenesis remains to be fully un-
derstood (Aguzzi and Zhu, 2017). Axonal degeneration is an
early feature of most neurodegenerative disorders including
prion diseases (Conforti et al., 2014). Axonal degeneration and
synaptic loss are observed both in Creutzfeldt-Jakob disease and
animal models of prion diseases (Guiroy et al., 1989; Jeffrey et al.,
1995; Liberski et al., 1995; Liberski and Budka, 1999; Ferrer,
2002; Gray et al., 2009; Reis et al., 2015) and often precede
neuronal death. However, the mechanism of axon degeneration
and its contribution to prion pathogenesis remain unknown.
In this study, we aimed to ascertain whether SARM1-
mediated innate immunity and/or SARM1-dependent axon
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degeneration might play a role in prion pathogenesis. We found
that SARM1 expression was decreased upon prion infection.
Prion inoculation experiments revealed that disease progression
was moderately accelerated by SARM1 deﬁciency. Analysis of
the neuroinﬂammatory response failed to ﬁnd any difference
between prion-infected SARM1−/−, SARM1+/−, and their WT lit-
termates (SARM1+/+), indicating that SARM1-mediated innate
immunity does not account for the deceleration of prion pro-
gression. We then performed a genome-wide transcriptome
analysis of SARM1+/+ and SARM1−/− mouse brains with or
without prion infection. Surprisingly, we found that SARM1
ablation led to an up-regulated expression of the pro-apoptotic
gene X-linked inhibitor of apoptosis (XIAP)–associated factor
1 (XAF1; Liston et al., 2001), resulting in enhanced pro-apoptotic
caspase activity and neuronal death in prion-infected SARM1−/−
mice. In vitro experiments demonstrated that the increased
susceptibility of SARM1-silenced neuronal cells to apoptotic
stimuli were abrogated by ablating XAF1. Hence, SARM1 deﬁ-
ciency sensitizes mice to prion-induced neurodegeneration,
probably by creating an XAF1-driven pro-apoptotic environ-
ment within neurons.
Results and discussion
Down-regulation of SARM1 expression in prion-infected
mouse brains
To determine whether the expression of SARM1 is altered by
prion infection, we performed quantitative real-time PCR (qRT-
PCR) on mRNA isolated from terminally scrapie-sickWT C57BL/6
mice infected with the Rocky Mountain Laboratory strain of
mouse-adapted scrapie prions (passage #6, therefore named
RML6). For comparison, we used age-matched WT C57BL/6 mice
inoculated with noninfectious brain homogenates (NBHs). We
found that Sarm1 mRNA was signiﬁcantly reduced in prion-
infected mouse brains (Fig. 1 A). In contrast, other members of
TLRs and adaptor molecules were either up-regulated or un-
changed upon prion infection (Fig. 1, B–D), suggesting that SARM1
is unique among TLR-associated molecules in its modulation by
prion infection.
We then performed Western blot analyses to assess the
SARM1 protein level in RML6- or NBH-inoculated mouse brains.
Again, we observed that the SARM1 protein level was signiﬁ-
cantly suppressed in RML6-infected C57BL/6 mouse brains
(Fig. 1, E and F; and Fig. S1). When the SARM1 signal was nor-
malized against neuronal markers, the relative SARM1 level was
still lower in RML6-infected samples compared with NBH-
treated samples, indicating that the suppression of SARM1 in
prion-infected mouse brains was not solely due to neuronal
death at the terminal stage of disease (Fig. 1, F and G; and Fig. S1)
but rather by prion-speciﬁc events (such as prion-induced
stresses to the neurons).
SARM1 deﬁciency resulted in accelerated prion progression
We found that SARM1 deﬁciency does not affect the expression of
PrPC in mouse brains (Fig. 2, A and B). To determine whether the
SARM1-mediated innate immune responses and/or axonal de-
generation may inﬂuence prion pathogenesis, we intracerebrally
inoculated SARM1−/−, SARM1+/−, and SARM1+/+ littermates with
RML6 prions. We found that SARM1 deﬁciency accelerated prion
disease. SARM1−/− mice experienced signiﬁcantly shortened in-
cubation times compared with isogenic WT littermates (median
survival, 166 d after inoculation [dpi] for SARM1−/− vs. 176 dpi for
WT littermates; P = 0.01). SARM1+/− mice showed a trend toward
acceleration that did not reach statistical signiﬁcance (median
survival, 171 dpi; Fig. 2 C). These results indicate that SARM1
deﬁciency accelerates prion progression and suggest a possible
effect of SARM1 haploinsufﬁciency, implying that SARM1 instead
plays a neuroprotective role in prion pathogenesis. The effect of
SARM1 deﬁciency on prion progression was moderate, but it was
statistically signiﬁcant, and its magnitude is comparable to that
seen in other genetically modiﬁed animal models or upon phar-
macological treatments (Sakai et al., 2013; Grizenkova et al., 2014;
Sorce et al., 2014; Herrmann et al., 2015; Zhu et al., 2016; Goniotaki
et al., 2017).
To compare the prion pathogenesis between SARM1−/−,
SARM1+/−, and SARM1+/+ mice, brains were collected synchro-
nously from prion-infected SARM1−/−, SARM1+/−, and SARM1+/+
mice at 112 dpi, a time point at whichmice did not reach terminal
stage. Histology of brains from SARM1−/−, SARM1+/−, and SARM1+/+
mice harvested at 112 dpi failed to reveal any obvious difference
in lesion patterns and PrPSc deposition in different areas
(Fig. 2 D). Western blots detecting proteinase K (PK)–resistant
prion protein (PrPSc) conﬁrmed a similar level of PrPSc accu-
mulation at 112 dpi (Fig. 2 E). Therefore, SARM1 deﬁciency
neither changed prion-induced lesion pattern nor altered PrPSc
accumulation.
Prion diseases are associated with axon degeneration. Ac-
cordingly, we found neuroﬁlaments NF70 and NF200 to be de-
creased in prion-infected mouse brains (Fig. 2, F–L; and Fig. S1).
SARM1 is required for axon degeneration induced by various
stimuli. However, in the RML mouse model of prion disease,
prion pathogenesis was aggravated in SARM1−/− mice. The ac-
celeration of prion progression by SARM1 deﬁciency therefore
implies that SARM1-mediated axon degeneration does not play a
major role in prion pathogenesis. Consistent with this assertion,
Western blot and immunohistochemistry of the neuroﬁlaments
NF70 and NF200, as well as the protein levels of pre- and
postsynaptic proteins SNAP25 and PSD95, failed to show obvi-
ous differences between SARM1−/−, SARM1+/−, and SARM1+/+
mouse brains at 112 dpi (Fig. 2, M–V; and Fig. S1). This is in
accordance with a previous report that slow Wallerian degen-
eration mice displayed unaltered prion pathogenesis (Gültner
et al., 2009).
SARM1 deﬁciency does not alter
prion-induced neuroinﬂammation
Upon challenge with WNV, SARM1−/− mice show increased viral
replication in the brain stem and enhanced mortality associated
with decreased microglial activation and reduced level of TNFα;
Szretter et al., 2009). Therefore, we set out to assess the extent
of neuroinﬂammation in prion-infected SARM1−/−, SARM1+/−,
and SARM1+/+ mice. We performed Iba1 immunohistochemical
staining to evaluate microglial activation in SARM1−/−, SARM1+/−,
and SARM1+/+ mouse brains collected at 112 dpi and observed a
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Figure 1. Reduced expression of SARM1 in prion-infected mouse brains. (A–C) qRT-PCR for Sarm1 (A), MyD88 family (B), and TLR (C) mRNA from
terminally sick RML6-infected C57BL/6 mice and age-matched NBH-inoculated C57BL/6 mice (n = 4). Relative expression was normalized to GAPDH expression
and represented as the percentage of average values in NBH-treated mice. (D) Summary of the qRT-PCR results. (E and F)Western blot for SARM1, actin, Syp,
and NeuN on brains collected from terminally sick RML6-infected C57BL/6 mice and NBH-inoculated C57BL/6 mice. (G) Densitometric quantiﬁcation of the
SARM1 Western blot. n = 5 for NBH-treated mice and n = 4 for RML6-treated mice. Relative signal intensity was represented as the percentage of average
values in NBH-treated mice (n = 5). qRT-PCR andWestern blot results represent at least three independent experiments. n.s., P > 0.05; *, P < 0.05; **, P < 0.01;
***, P < 0.001. Data are shown as mean ± SEM.
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similar level of microglial activation in all three groups (Fig. 3, A
and B). Sholl analysis of the microglial morphology (Kongsui
et al., 2014; Papageorgiou et al., 2016) showed a similar pattern
of microglial activation between the three groups (Fig. 3 C).
Western blot of Iba1 conﬁrmed that SARM1−/−, SARM1+/−, and
SARM1+/+ mouse brains experienced similar levels of microglial
activation (Fig. 3 D and Fig. S1). Additionally, we found a similar
number of CD68+ cells (representing activated microglia) in
various regions in SARM1−/−, SARM1+/−, and SARM1+/+ mouse
brains (Fig. 3 E). Therefore, SARM1 deﬁciency does not alter
prion-induced microglial activation. We also performed GFAP
(glial ﬁbrillary acidic protein) immunohistochemical staining to
assess astrogliosis. There were no overt differences between the
different genotypes (Fig. 3 F). Western blot of GFAP conﬁrmed
that SARM1−/−, SARM1+/−, and SARM1+/+ mouse brains experi-
enced similar levels of astrogliosis at 112 dpi (Fig. 3 G and Fig. S1).
Furthermore, cytokine proﬁling showed similar levels of Tnfα,
Il-1β, and Il-6 mRNAs in SARM1−/−, SARM1+/−, and SARM1+/+
mouse brains at 112 dpi (Fig. 3 H). Therefore, SARM1 deﬁciency
does not overtly alter prion-induced neuroinﬂammation.
The acceleration of prion pathogenesis by SARM1 ablation is
consistent with ﬁndings in a WNV infection model, where
SARM1−/− mice experienced enhanced mortality. However, the
pathomechanisms appear to differ between WNV and prion
infections. WNV-infected SARM1−/− mice showed decreased
microglial activation and reduced levels of TNFα, whereas
prion-infected SARM1−/− mice failed to show any difference in
microglial activation, astrogliosis, or cytokine production.
SARM1 deﬁciency leads to XAF1 up-regulation and
enhanced apoptosis
In an effort to discover how SARM1 deﬁciency accelerates prion
progression, we performed whole-transcriptome analyses of
SARM1−/− and SARM1+/+ mouse brains with or without prion
infection by RNA sequencing (RNaseq). Surprisingly, only very
few geneswere differentially expressed in SARM1−/− and SARM1+/+
mouse brains. Of these, only SARM1 itself and XAF1 showed
strong down- or up-regulation (fold change >2, P < 0.01) in both
uninfected and prion-infected brains (Fig. 4, A and B; and Table
S1). We then veriﬁed the RNaseq results by qRT-PCR. XAF1
mRNA was signiﬁcantly up-regulated by SARM1 deﬁciency in a
gene dose–dependent manner (Fig. 4 C). Interestingly, we ob-
served that prion infection itself up-regulated XAF1 expression,
even in the absence of SARM1 (Fig. 4 C). Therefore, prion in-
fection and SARM1 deﬁciency synergistically up-regulated
XAF1 expression in prion-infected SARM1−/− mice.
A previous study showed up-regulation of XAF1 mRNA in a
different SARM1-deﬁcient mouse line but claimed that XAF1
protein levels remained unaltered (Hou et al., 2013). We have
tested several anti-XAF1 antibodies to detect increased levels of
XAF1 protein in SARM1−/− and prion-infected mouse brains.
However, all tested anti-XAF1 antibodies failed to detect a spe-
ciﬁc XAF1 band. The anti-XAF1 antibody from Aviva Systems
Biology (OAAB14914) could detect transiently overexpressed
XAF1 in mouse neuronal CAD5 cells (XAF1 mRNA >180-fold up-
regulated) but not endogenous XAF1 in CAD5 cells or mouse
brains (Fig. S2). Our results suggest that the failure of detecting
increased levels of XAF1 protein is mainly due to the lack of
speciﬁc and sufﬁciently sensitive anti-mouse XAF1 antibodies.
The murine XAF1 and SARM1 loci are both located on chro-
mosome 11 with a distance of 2.75 cM. The ablation of the SARM1
gene may conceivably alter XAF1 expression by affecting the
chromosomal structure of neighboring loci, or by cosegregating
with polymorphic DNA loci. To test these possibilities, we per-
formed siRNA silencing of SARM1 in CAD5 cells. Also in this
paradigm, the knockdown of SARM1 signiﬁcantly up-regulated
XAF1 expression (Fig. 4, D–F; and Fig. S1). These results suggest
that SARM1 regulates XAF1 expression in trans, and this regu-
lation is cell autonomous. The mechanisms underlying this
regulation may involve miRNAs and/or epigenetic regulation
(Byun et al., 2003; Zou et al., 2006; Lee et al., 2011).
To further investigate whether SARM1 deﬁciency leads to up-
regulation of XAF1 in a cell-autonomous manner in prion-
infected mouse brains, we performed in situ hybridization of
SARM1 and XAF1 on formalin-ﬁxed, parafﬁn-embedded brain
sections using the RNAscope technology. Again, we found that
SARM1 and XAF1 mRNA signals colocalized predominantly in
synaptophysin (Syp)-positive neurons and SARM1 deﬁciency
Figure 2. SARM1 deﬁciency accelerated prion progression. (A) qRT-PCR for PrnpmRNA in SARM1−/−, SARM1+/–, and SARM1+/+ mouse brains. n = 4 for each
genotype. (B) Western blot for PrPC in SARM1−/− and SARM1+/+ mouse brains. (C) Survival curves of RML6-infected SARM1−/−, SARM1+/−, and SARM1+/+ mice.
The median survival of SARM1−/−mice was 166 dpi (n = 23), whereas that of SARM1+/+ mice was 176 dpi (n = 29). The median survival of SARM1+/– mice was 171
dpi (n = 41). The survival curves summarize three independent intracerebral inoculation experiments of 22, 25, and 46 mice, respectively. (D) H&E and im-
munostainings for SAF84 (which detects PrP) on RML6-infected SARM1−/−, SARM1+/–, and SARM1+/+ brains at 112 dpi. Left: Hippocampus. Right: Cerebellum.
Bars, 200 µm. (E) Left: PrPSc Western blot of RML6-infected SARM1−/−, SARM1+/–, and SARM1+/+ brain homogenates at 112 dpi. Right: Densitometric quan-
tiﬁcation of the PrPSc Western blot. n = 3 for each genotype. (F–L)Western blot and immunohistochemistry of brain for NF70 (F and I) and NF200 (G and J) in
terminally sick RML6-infected C57BL/6 mice and NBH-inoculated C57BL/6 mouse brains. (H) Densitometric quantiﬁcation of NF70 and NF200 Western blot
showing dramatic NF70 and NF200 reduction in RML6-infected brains. (K and L)Quantiﬁcation of NF70 and NF200 staining in cerebellum (K) and thalamus (L)
showed decreased NF70 and NF200 staining in RML6-infected brains. n = 5 for NBH-treated and RML6-treated mice. Bars, 200 µm. (M–S)Western blot and
immunohistochemistry of brain tissues for NF70 (M and P) and NF200 (N and Q) in RML6-infected SARM1−/−, SARM1+/−, and SARM1+/+ mouse brains at 112 dpi.
(O) Densitometric quantiﬁcation of NF70 and NF200 Western blots showed unchanged NF70 and NF200 levels. n = 3 for each genotype. (R and S) Quan-
tiﬁcation of NF70 and NF200 staining in cerebellum (R) and thalamus (S) showed unaltered NF70 and NF200 staining. n = 4 for SARM1+/− and SARM1+/+ mice;
n = 8 for SARM1−/− mice. Bars, 200 µm. (T and U)Western blots for SNAP25 (T) and PSD95 (U) in RML6-infected SARM1−/−, SARM1+/−, and SARM1+/+ mouse
brains at 112 dpi. (V) Densitometric quantiﬁcation of the SNAP25 and PSD95 Western blots showed unchanged protein levels. n = 3 for each genotype. qRT-
PCR, Western blot, and histology results represent at least three independent experiments. Relative signal intensity of Western blot was represented as the
percentage of average values in NBH-treated or SARM1+/+ mice. The immunohistochemical staining was calculated as the percentage of brown signals over the
total area. n.s., P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data are shown as mean ± SEM.
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increased XAF1 signals in neurons (Fig. 4 G). Interestingly, we
also observed SARM1 signals in SARM1−/−mouse brains in which
exons 1–2 are deleted, indicating that the RNAscope SARM1
probes (20 pairs of Z RNA probe targeting exons 2–6) could still
recognize the truncated SARM1 transcripts containing exons
3–6. These results conﬁrm that the up-regulation of XAF1 ex-
pression by SARM1 depletion in vivo is also cell autonomous.
XAF1 is a pro-apoptotic molecule that antagonizes the
caspase-inhibitory activity of XIAP by redistributing XIAP from
the cytosol to the nucleus (Liston et al., 2001). Abolishing XAF1
expression increases the resistance of cell lines to apoptosis,
whereas overexpression of XAF1 sensitizes motoneurons to ax-
otomy and the ﬁrst trimester trophoblast cells to Fas-mediated
apoptosis (Perrelet et al., 2004; Straszewski-Chavez et al., 2007).
We therefore set out to assess whether SARM1-deﬁcient mice
might experience enhanced apoptosis after prion infection. We
performed caspase 3 and caspase 9 activity assays by measuring
their DEVDase and LEHDase activities, respectively. Indeed,
RML6-infected SARM1−/− brains showed signiﬁcantly higher
caspase 3 and caspase 9 activity (Fig. 5, A and B) than SARM1+/+
brains collected at 112 dpi. TUNEL (terminal deoxynucleotidyl
transferase dUTP nick end labeling) staining showed that apo-
ptosis was more prevalent in RML6-infected SARM1−/− brains
than in SARM1+/+ brains at 112 dpi (Fig. 5 C). Accordingly, the
neuronal marker synapsin I, which was decreased in terminally
prion-sick mice (Fig. 5 D and Fig. S1) but not altered by SARM1
deﬁciency in uninfected mice (Fig. 5 E), was signiﬁcantly lower
in prion-infected SARM1−/− brains at 112 dpi (Fig. 5 F and Fig. S1).
These results suggest that SARM1 deﬁciency sensitizes mice to
prion-induced apoptosis, leading to enhanced neuronal death.
It has been reported that XAF1 may cooperate with TNFα to
induce apoptosis and increase expression of XAF1-sensitized
cells to apoptosis (Xia et al., 2006; Straszewski-Chavez et al.,
2007). To establish whether the enhanced susceptibility to ap-
optosis by SARM1 deﬁciency is due to the up-regulation of XAF1,
we ﬁrst silenced SARM1 in CAD5 cells and then treated them
with TNFα. We found that while TNFα led to apoptosis and re-
duced cell numbers in both SARM1-silenced and nontarget
siRNA treated cells, apoptosis was enhanced and cell numbers
were more conspicuously reduced in SARM1-silenced cells
(Fig. 5, G–I). However, when the same treatment was performed
on XAF1 KO CAD5 cells generated by the CRISPR/Cas9 system
(Fig. 5 J), the enhancement by SARM1 silencing was abrogated
(Fig. 5, G–I), indicating that SARM1 deﬁciency sensitized cells to
apoptotic stimuli mainly through the up-regulated XAF1.
Therefore, it is conceivable that the deterioration of prion
pathogenesis in SARM1−/− mice may be due to the up-regulated
XAF1 and consequently enhanced apoptosis.
In summary, we found that SARM1 deﬁciency unexpectedly
accelerated prion progression. SARM1 deﬁciency selectively up-
regulated expression of the pro-apoptotic protein XAF1, which,
in turn, enhanced apoptosis in prion-infected SARM1−/− mice.
Since the effects appear to be gene-dosage dependent, XAF1
repression may potentially ameliorate prion-related neuronal
pathologies.
Materials and methods
Ethical statement
All animal experiments were performed in strict accordance
with the Rules and Regulations for the Protection of Animal
Rights (Tierschutzgesetz and Tierschutzverordnung) of the Swiss
Bundesamt für Lebensmittelsicherheit und Veterina¨rwesen
and were preemptively approved by the Animal Welfare
Committee of the Canton of Zürich (permit 41/2012).
Animals
SARM1−/−mice (Szretter et al., 2009) carrying a targeted deletion
of exons 1–2wereﬁrst backcrossed to C57BL/6J to obtain SARM+/−
offspring. SARM+/− mice were then intercrossed to obtain
SARM1−/−, SARM+/−, and SARM1+/+ (WT) littermates, which were
used for the experiments described here. Mice were main-
tained in a high hygienic-grade facility and housed in groups of
3–5, under a 12-h light/12-h dark cycle (from 7 a.m. to 7 p.m.) at
21 ± 1°C, with sterilized food (3436; Provimi Kliba) and water
provided ad libitum.
Intracerebral prion inoculation
Mice at 6–8 wk old were intracerebrally inoculated with 30 µl of
brain homogenate diluted in PBS with 5% BSA and containing
3 × 105 LD50 units of the RML6. Scrapie was diagnosed according
to clinical criteria (ataxia, kyphosis, priapism, and hind-leg pa-
resis). Mice were sacriﬁced on the day of onset of terminal
clinical signs of scrapie.
qRT-PCR
Total RNA from brain was extracted using TRIzol (Invitrogen
Life Technologies) according to the manufacturer’s instructions.
Figure 3. Unaltered neuroinﬂammation in prion-infected SARM1−/− mouse brains. (A) Iba1 immunohistochemistry of brain tissues from RML6-infected
SARM1−/−, SARM1+/–, and SARM1+/+ mice at 112 dpi. Bars, 100 µm. (B) Quantiﬁcation of Iba1 staining in hippocampus (left) and cerebellum (right). n = 4 for
SARM1+/– and SARM1+/+ mice; n = 8 for SARM1−/−mice. (C) Sholl analysis of Iba1-positive microglia in RML6-infected SARM1−/−, SARM1+/–, and SARM1+/+ mouse
brains at 112 dpi. (D) Left: Western blot for Iba1 in RML6-infected SARM1−/−, SARM1+/–, and SARM1+/+ mouse brains at 112 dpi. Right: Densitometric quan-
tiﬁcation of the Iba1Western blot. n = 3 for each genotype. (E) Left: CD68 immunohistochemistry of brain tissues from RML6-infected SARM1−/−, SARM1+/–, and
SARM1+/+ mice at 112 dpi. Bars, 100 µm. Right: Quantiﬁcation of CD68-positive cells. n = 5∼10. (F) GFAP immunohistochemistry of brain tissues from RML6-
infected SARM1−/−, SARM1+/−, and SARM1+/+ mice at 112 dpi. Bars, 100 µm. (G) Left: Western blot for GFAP in RML6-infected SARM1−/−, SARM1+/−, and SARM1+/+
mouse brains at 112 dpi. Right: Densitometric quantiﬁcation of the GFAPWestern blot. n = 3 for each genotype. (H) qRT-PCR of cytokines (Tnfα, Il-1β, and Il-6)
in RML6-infected SARM1−/−, SARM1+/–, and SARM1+/+ mouse brains at 112 dpi. n = 8 for SARM1−/− and n = 4 for SARM1+/– and SARM1+/+ mice. Relative expression
was normalized to GAPDH expression and represented as the percentage of average values in SARM1+/+ mice. Histology, Western blot, and qRT-PCR results
represent at least three independent experiments. Relative signal intensity of Western blot was represented as the percentage of average values in SARM1+/+
mice. The immunohistochemical staining was calculated as the percentage of brown signals over the total area. n.s., P > 0.05. Data are shown as mean ± SEM.
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The quality of RNA was analyzed by Bioanalyzer 2100 (Agilent
Technologies); RNAs with an RNA integrity number >7 were
used for cDNA synthesis. cDNAs were synthesized from ∼1 µg
total RNA using a QuantiTect Reverse Transcription kit (Qiagen)
according to the manufacturer’s instructions. qRT-PCR was
performed using the SYBR Green PCR Master Mix (Roche) on a
ViiA7 Real-Time PCR system (Applied Biosystems).
The following primer pairs were used: GAPDH sense 59-CCA
CCCCAGCAAGGAGACT-39; antisense, 59-GAAATTGTGAGGGAG
ATGCT-39; Sarm1 (Myd88-5) sense, 59-CGCTGCCCTGTACTG
GAGG-39; antisense, 59-CTTCAGGAGGCTGGCCAGCT-39; Myd88
sense, 59-TCATGTTCTCCATACCCTTGGT-39; antisense, 59-AAA
CTGCGAGTGGGGTCAG-39; Tirap (Myd88-2) sense, 59-CCTCCT
CCACTCCGTCCAA-39; antisense, 59-CTTTCCTGGGAGATCGGC
AT-39; Ticam1 (Myd88-3) sense, 59-CCAGCTCAAGACCCCTAC
AG-39; antisense, 59-CAAGGCACCTAGAATGCCAAA-39; Ticam2
(Myd88-4) sense, 59-CGATCAAGACGGCCATGAGTC-39; anti-
sense, 59-CTCGTCGGTGTCATCTTCTGC-39; Tlr1 sense, 59-TGA
GGGTCCTGATAATGTCCTAC-39; antisense, 59-AGAGGTCCAAAT
GCTTGAGGC-39; Tlr2 sense, 59-GCAAACGCTGTTCTGCTCAG-39;
antisense, 59-AGGCGTCTCCCTCTATTGTATT-39; Tlr3 sense, 59-
GTGAGATACAACGTAGCTGACTG-39; antisense, 59-TCCTGCATC
CAAGATAGCAAGT-39; Tlr4 sense, 59-AGGCACATGCTCTAGCAC
TAA-39; antisense, 59-AGGCTCCCCAGTTTAACTCTG-39; Tlr5
sense, 59-GCAGGATCATGGCATGTCAAC-39; antisense, 59-ATC
TGGGTGAGGTTACAGCCT-39; Tlr6 sense, 59-TGAGCCAAGACA
GAAAACCCA-39; antisense, 59-GGGACATGAGTAAGGTTCCTG
TT-39; Tlr7 sense, 59-ATGTGGACACGGAAGAGACAA-39; anti-
sense, 59-GGTAAGGGTAAGATTGGTGGTG-39; Tlr8 sense, 59-
GAAAACATGCCCCCTCAGTCA-39; antisense, 59-CGTCACAAG
GATAGCTTCTGGAA-39; Tlr9 sense, 59-ATGGTTCTCCGTCGA
AGGACT-39; antisense, 59-GAGGCTTCAGCTCACAGGG-39; Tnfα
sense, 59-CATCTTCTCAAAATTCGAGTGACAA-39; antisense, 59-
TGGGAGTAGACAAGGTACAACCC-39; Il-1β sense, 59-CAACCA
ACAAGTGATATTCTCCATG-39; antisense, 59-GATCCACACTCT
CCAGCTGCA-39; Il-6 sense, 59-TCCAATGCTCTCCTAACAGAT
AAG-39; antisense, 59-CAAGATGAATTGGATGGTCTTG-39; and
Xaf1 sense, 59-GAAGCTTGACCATGGAGGCT-39; antisense, 59-
GGTGCACAACTTCCATGTGCT-39. Expression levels were nor-
malized using GAPDH.
Western blot analysis
To detect SARM1 and PrPC in the mouse brains, one hemisphere
from each brain was homogenized with buffer PBS contain-
ing 0.5% Nonidet P-40 and 0.5% 3-([3-cholamidopropyl]
dimethylammonio)-2-hydroxy-1-propanesulfonate (CHAPSO).
Total protein concentration was determined using the bicin-
choninic acid assay (Pierce). Approximately 20 µg protein were
loaded and separated on a 12% Bis-Tris polyacrylamide gel
(NuPAGE; Invitrogen) and then blotted onto a nitrocellulose
membrane. Membranes were blocked with 5% wt/vol Topblock
(LuBioScience) in PBS supplemented with 0.05% Tween 20
(vol/vol) and incubated with primary antibodies anti-SARM1
(D2M5I) rabbit mAb (1:1,000; 13022; Cell Signaling Technology)
or POM1 (200 ng/ml) in 1% Topblock overnight. After washing,
the membranes were then incubated with secondary antibody
HRP-conjugated goat anti-rabbit IgG (1:10,000; 111-035-045;
Jackson ImmunoResearch) or goat anti–mouse IgG (1:10,000;
115-035-003; Jackson ImmunoResearch). Blots were developed
using Luminata Crescendo Western HRP substrate (Millipore)
and visualized using the Stella system (model 3200; Raytest).
To avoid variation in loading, the same blots were stripped and
incubated with an anti-actin antibody (1:10,000; MAB1501R;
Millipore). The signals were normalized to actin as a loading
control. To detect PrPSc in prion-infected SARM1−/−, SARM+/−,
and SARM1+/+ (WT) mouse brains, prion-infected forebrains
were homogenized in sterile 0.32 M sucrose in PBS. Total
protein concentration was determined using the bicinchoninic
acid assay (Pierce). Samples were adjusted to 20 µg protein in a
20 µl prepared solution and digested with 25 µg/ml PK in di-
gestion buffer (PBS containing 0.5% wt/vol sodium deoxycho-
late and 0.5% vol/vol Nonidet P-40) for 30 min at 37°C. PK
digestion was stopped by adding loading buffer (Invitrogen)
and boiling samples at 95°C for 5 min. Proteins were then
separated on a 12% Bis-Tris polyacrylamide gel (NuPAGE; In-
vitrogen) and blotted onto a nitrocellulose membrane. POM1
and HRP-conjugated goat anti-mouse IgG were used as primary
and secondary antibodies, respectively. Blots were developed
using Luminata Crescendo Western HRP substrate (Millipore)
and visualized using the Fujiﬁlm LAS-3000 system. To detect
NeuN, Syp, NF70, NF200, SNAP25, PSD95, Iba-1, GFAP, and
synapsin I in prion-infected WT C57BL/6 mouse brains or
SARM1−/−, SARM1+/−, and SARM1+/+ (WT) mouse brains, 20 µg of
total brain protein were loaded and anti-NeuN clone EPR12763
(ab177487; Abcam), anti-synaptophysin clone 2/Syp (611880;
BD Biosciences), anti–neuroﬁlament-L clone DA2 (1:1,000;
2835; Cell Signaling Technology), anti-neuroﬁlament 200
clone NE14 (1:1,000; N5389; Sigma), anti-SNAP25 antibody
(1:1,000; ab5666; Abcam), anti-PSD95 antibody (1:1,000;
18258; Abcam), anti–Iba-1 antibody (1:1,000; Wako
Figure 4. SARM1 deﬁciency and prion infection up-regulated XAF1 expression in mouse brains. (A and B) Volcano plots of RNaseq data for uninfected
(A) and RML6-infected (112 dpi; B) SARM1−/− and WT mouse brains. Signiﬁcants (red dots) are genes that show log2 ratios >1 or < −1 (fold change >2) with P <
0.01. (C) qRT-PCR of Xaf1 in uninfected and RML6-infected (112 dpi) SARM1−/−, SARM1+/–, and SARM1+/+ mouse brains. n = 3–4 for each group. Relative
expression was normalized to GAPDH expression and represented as the percentage of average values in uninfected SARM1+/+ mice. (D and E) qRT-PCR of
Sarm1 (D) and SARM1Western blot (E) in SARM1 siRNA-treated CAD5 cells. (F) qRT-PCR of Xaf1 in SARM1 siRNA-treated CAD5 cells. n = 6 for each treatment.
Relative expression was normalized to GAPDH expression and represented as the percentage of average values in nontarget control. (G) Upper panel: Images
of in situ hybridization using 3-Plex negative probes. Middle and lower panels: Representative images of Sarm1, Xaf1, and Syp in situ hybridization in RML6-
infected WT (middle) and SARM1−/− (lower) mouse cerebella, hippocampi, and neocortex at 112 dpi. Differential interference contrast (DIC) and DAPI staining
show the morphology and nuclei of cells. gl, granular layer; ml, molecular layer; pl, Purkinje cell layer. White arrows indicate Sarm1, Xaf1, and Syp triple-positive
cells. Bars, 20 µm. qRT-PCR and Western blot results represent at least three independent experiments. In situ hybridization represents two independent
experiments. n.s., P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are shown as mean ± SEM.
Zhu et al. Journal of Experimental Medicine 9
SARM1 deﬁciency accelerates prion disease https://doi.org/10.1084/jem.20171885
Zhu et al. Journal of Experimental Medicine 10
SARM1 deﬁciency accelerates prion disease https://doi.org/10.1084/jem.20171885
Chemicals GmbH), anti-GFAP antibody (D1F4Q) XP Rabbit
mAb (1:3,000; 12389; Cell Signaling Technology), and anti–
synapsin I (1:2,000; AB1543; Millipore AG) were used. To detect
XAF1 in mouse brains and CAD5 cells, primary antibodies
rabbit anti-mouse XAF1 antibody (1:1,000; ab17204 and
ab81353 [Abcam]; OAAB14914 [Aviva Systems Biology];
A03432 [Boster]; PA1-41099 [Invitrogen]; GTX51339 [Gene-
Tex]; NB100-56355 [Novus Biologicals]) were used. Actin was
used as a loading control.
Immunohistochemistry
For immunohistochemistry of prion-infected brains, formalin-
ﬁxed tissues were treated with concentrated formic acid for
60 min to inactivate prion infectivity and embedded in par-
afﬁn. Parafﬁn sections (2 µm) of brains were stained with
H&E. After deparafﬁnization through graded alcohols, Iba-
1 antibody (1:1,000; Wako Chemicals GmbH) was used for
highlighting microglial cells, GFAP antibody (1:300; DAKO)
was used for astrocytes, anti-neuroﬁlament 70 clone 2F11 (1:
100; M076229-2; DAKO) and anti-neuroﬁlament 200 clone
NE14 (1:2,000; N5389; Sigma) antibodies were used for as-
sessing axonal degeneration. Stainings were visualized using
an IVIEW DAB Detection Kit (Ventana), with a hematoxylin
counterstain applied subsequently. For the histological de-
tection of partially PK-resistant prion protein deposition,
deparafﬁnized sections were pretreated with formaldehyde
for 30 min and with 98% formic acid for 6 min, and then
washed in distilled water for 30 min. Sections were incubated
in Ventana buffer, and stains were performed on a NEXEX
immunohistochemistry robot (Ventana) using an IVIEW DAB
Detection Kit (Ventana). After incubation with protease
1 (Ventana) for 16 min, sections were incubated with anti-PrP
SAF-84 (1:200; A03208; SPI Bio) for 32 min. Sections were
counterstained with hematoxylin. Sections were imaged us-
ing a Zeiss Axiophot light microscope. Quantiﬁcation of Iba-1,
GFAP, NF70, and NF200 staining was performed on ac-
quired images, where regions of interest were drawn, and
the percentage of brown Iba-1, GFAP, NF70, and NF200
staining over the total area was quantiﬁed using ImageJ
software (National Institutes of Health). For CD68 staining,
4% paraformaldehyde-ﬁxed brain tissues were cut into 10-µm
cryosections and stained with anti-CD68 antibody clone FA-11
(MCA1957; Bio-Rad) and visualized by Alexa 546 conjugated
goat-anti-rat antibody (A11081; Invitrogen). The nuclei were
counterstained with DAPI. Images were captured using confo-
cal laser scanning microscope FluoView Fv10i (Olympus). The
operator was blinded to the genotype and treatment of the
analyzed tissues.
RNaseq
Total RNA from brain was extracted using TRIzol (Invitrogen
Life Technologies) according to the manufacturer’s instruction,
followed by RNA cleanup using an RNeasy kit (Qiagen). The
quality of RNA was analyzed by Bioanalyzer 2100 (Agilent
Technologies), RNAs with RNA integrity number >8 were fur-
ther processed. The TruSeq Stranded mRNA Sample Prep Kit
(Illumina, Inc.) was used in the succeeding steps. Brieﬂy, total
RNA samples (500 ng) were poly-A selected and then reverse-
transcribed into double-stranded cDNA with actinomycin added
during ﬁrst-strand synthesis. The cDNA samples were frag-
mented, end-repaired, and adenylated before ligation of TruSeq
adapters. The adapters contain the index for multiplexing.
Fragments containing TruSeq adapters on both ends were se-
lectively enriched with PCR. The quality and quantity of the
enriched libraries were validated using Qubit (1.0) Fluorometer
(Life Technologies) and the Bioanalyzer 2100 (Agilent Technol-
ogies). The product is a smear with an average fragment size of
∼360 bp. The libraries were normalized to 10 nM in Tris-Cl 10
mM, pH 8.5, with 0.1% Tween 20. The TruSeq SR Cluster Kit v4-
cBot-HS (Illumina, Inc.) was used for cluster generation using 8
pM of pooled normalized libraries on the cBOT. Sequencing was
performed on the Illumina HiSeq 4000 single-end 125 bp using
the TruSeq SBS Kit v4-HS (Illumina, Inc.). Reads were quality-
checked with FastQC. For RNaseq data analysis, we used RSEM
to performRNaseq read alignment and expression estimation (Li
and Dewey, 2011). As reference we used the GRCm38 genome
assembly and the corresponding gene annotations provided by
Ensembl. We computed differential expression with the Bio-
conductor package DESeq2 (Love et al., 2014). A gene was con-
sidered as differentially expressed by applying a threshold of
Figure 5. SARM1 deﬁciency enhanced apoptosis in prion-infected SARM1−/− brains. (A and B) Caspase 3 (A) and caspase 9 (B) activity assay of RML6-
infected SARM1−/−, SARM1+/−, and SARM1+/+ mouse brains at 112 dpi. n = 8 for SARM1−/− and n = 4 for SARM1+/− and SARM1+/+ mice. Relative caspase 3 and
caspase 9 activity was represented as the percentage of average values in SARM1+/+ mice. (C) Left: TUNEL staining of brain tissues from RML6-infected
SARM1−/−, SARM1+/−, and SARM1+/+ mice at 112 dpi. Right: Quantiﬁcation of TUNEL-positive cells. n = 7 for SARM1−/− and n = 3 for SARM1+/− and SARM1+/+ mice.
Bars, 10 µm. (D) Upper: Western blot for synapsin I on brains collected from terminally sick RML6-infected C57BL/6 mice and NBH-inoculated C57BL/6 mice.
Lower: Densitometric quantiﬁcation of the synapsin I Western blot showed a signiﬁcant reduction of synapsin I in RML6-infected brains. n = 5 for NBH-treated
and RML6-treated mice. (E) Left: Western blot for synapsin I in uninfected SARM1−/−, SARM1+/−, and SARM1+/+ mice. Right: Densitometric quantiﬁcation of the
synapsin I Western blots showed unchanged synapsin I level in uninfected SARM1−/−, SARM1+/−, and SARM1+/+ mice. n = 3 for SARM1+/− and SARM1+/+ mice; n = 5
for SARM1−/− mice. (F) Left: Western blot for synapsin I in RML6-infected SARM1−/−, SARM1+/−, and SARM1+/+ mouse brains at 112 dpi. Right: Densitometric
quantiﬁcation of the synapsin I Western blot. n = 3 for each genotype. (G) Caspase 3 activity assay of WT CAD5 and XAF1 KO CAD5 cell lysates after SARM1
siRNAs and TNFα treatments. (H) Caspase 9 activity assay of WT CAD5 and XAF1 KO CAD5 cell lysates after SARM1 siRNAs and TNFα treatments. n = 3.
Relative caspase 3 and caspase 9 activity was represented as the percentage of average values in PBS groups. (I) RealTime-Glo assay of liveWT CAD5 and XAF1
KO CAD5 cells after SARM1 siRNAs and TNFα treatments. n = 6. Relative cell numbers were represented as the percentage of average values in PBS groups.
Relative caspase 3 and caspase 9 activity measurement represents two independent experiments. (J) Sequencing results of the Xaf1 gene in XAF1 KO CAD5
cells showed that the coding sequence of all sequenced clones was frameshifted. PAM, protospacer adjacent motif. Western blot results represent at least
three independent experiments. Relative signal intensity of Western blot was represented as the percentage of average values in NBH-treated or SARM1+/+
mice. n.s., P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are shown as mean ± SEM.
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0.01 for the P value and 1 for the log-ratio. Additionally, we
ﬁltered away genes that had very low counts. Speciﬁcally, we
did not consider a gene as expressed if it did not exceed in at
least one condition an average read count of 10 in the samples.
All clusterings and visualizations were performed with R/Bio-
conductor (R version 3.2). Data from RNaseq analyses have been
deposited to the Gene Expression Omnibus under the dataset
code GSE124932.
Establishment of XAF1 KO CAD5 cells by CRISPR/Cas9
A XAF1 knockout CAD5 cell line was established by CRISPR/Cas9
genome editing approach. Brieﬂy, a guide RNA targeting exon
1 of the XAF1 gene (59-AGGCTGACTTCCAAGTGTGC-39) was
cloned into the pKLV-U6gRNA(BbsI)-PGKpuro2ABFP vector
(Addgene 50946) to generate pKLV-XAF1 single guide RNA
plasmid. CAD5 cells were cotransfected with pKLV-XAF1 single
guide RNA and pCMV-hCas9 (Addgene 41815) in a molar ratio of
1:1 by Lipofectamine 2000 (11668-019; Invitrogen). Transfected
cells were selected and enriched by puromycin (2 µg/ml), and
single-cell clones were obtained by limited dilution. Cell clones
were grown and expanded. To conﬁrm gene editing of the XAF1
gene in cell clones, a region embracing exon 1 of the XAF1 gene
was PCR-ampliﬁed using a forward primer (59-GTCACAGTCACG
GTAGCACA-39) and reverse primer (59-GGGACCAGTCCCTCC
ATACT-39); the PCR product was cloned into pCR-Blunt II-TOPO
vector (45-0245; Invitrogen) and sequenced to verify the fra-
meshifted indels.
siRNA and TNFα treatment on CAD5 and XAF1 KO CAD5 cells
24 h before transfection, 2 × 105 CAD5 cells (murine neuronal
cell line) per well were seeded in 6-well plates. CAD5 cells were
then transfected with three different SARM1 siRNA (siRNA ID:
s108645, s108646, and s108647; Thermo Fisher Scientiﬁc) or
nontarget negative control siRNA (4390843; Thermo Fisher
Scientiﬁc) at 50 nM concentration using Lipofectamine RNAi-
MAX. 48 h after transfection, cells were harvested for total RNA
extraction and protein analysis.
For TNFα treatment, 2 × 104 CAD5 or XAF1 KO CAD5 cells per
well were ﬁrst seeded in 96-well plates and transfected with
SARM1 siRNAs or nontarget negative control siRNA. 24 h after
the transfection, cells were treated with TNFα at a concentration
of 50 ng/ml or PBS control for 72 h. Cell viability was assessed by
RealTime-Glo (G9713; Promage). The relative cell viability was
calculated as percentages to the PBS control groups.
RNAscope in situ hybridization
Transcripts of SARM1, XAF1, and Syp in formalin-ﬁxed,
parafﬁn-embedded brain sections were detected by in situ hy-
bridization using RNAscope Multiplex Fluorescent Reagent Kit
v2 (323100; Advanced Cell Diagnostics) following the manu-
facturer’s instructions. Brieﬂy, sections were deparafﬁnized and
pretreated with hydrogen peroxide and protease plus, followed
by hybridization with target probes (SARM1, 504191-C2; XAF1,
504181; Syp, 426521-C3), which are designed and manufactured
by Advanced Cell Diagnostics. 3-Plex negative control probes
targeting the DapB gene from the Bacillus subtilis strain SMY
(320871) were used as a negative control. After ampliﬁcation
steps, ﬂuorescence signals were developed by TSA Plus
ﬂuorophores kits (ﬂuorescein, NEL741E001KT; Cyanine 3,
NEL744E001KT; Cyanine 5, NEL745001KT; PerkinElmer). Im-
ages were captured using a Leica TCS SP5 confocal microscope.
Caspase 3 and caspase 9 activity assay
Caspase 3 activity was measured by a caspase 3 assay kit
(ab39401; Abcam) and caspase 9 activity was measured by a
caspase 9 assay kit (ab65608; Abcam) according to the manu-
facturer’s instructions. Brieﬂy, brain homogenates or cell lysates
containing the same amount of total protein were incubated
with either DEVE-p-NA or LEHD-p-NA substrates. After cleav-
age, the p-NA light emission was quantiﬁed using a microtiter
plate reader at 405 nm. The activity of caspase 3 and caspase 9
was calculated as percentages to the SARM1+/+ (WT) control or
cell lysates treated with PBS.
TUNEL assay
Apoptosis in parafﬁn sections of prion-infected mouse brains were
assessed by an in situ BrdU-Red DNA fragmentation assay kit ac-
cording to the manufacturer’s instructions (ab66110; Abcam).
Brieﬂy, sections were deparafﬁnized and treated with PK, followed
by labeling of DNA nicks with Br-dUTP (bromolated deoxyuridine
triphosphate nucleotide) mediated by terminal deoxynucleotidyl
transferase. The incorporated BrdU was detected by ﬂuorescently
labeled anti-BrdU monoclonal antibody. The nuclei were coun-
terstained with DAPI. Images were captured using confocal laser
scanning microscope FluoView Fv10i (Olympus) and analyzed
using ImageJ software (National Institutes of Health).
Statistical analysis
Results are presented as the mean of replicas ± SEM. Unpaired
Student’s t test was used for comparing two samples. For in
vivo experiments, all groups were compared by log-rank
(Mantel-Cox) test. P values <0.05 were considered statisti-
cally signiﬁcant.
Online supplemental material
Fig. S1 shows full images of the cropped Western blots in main
ﬁgures, Fig. S2 shows the validation of various XAF1 antibodies
by Western blot. Table S1 presents the RNaseq results.
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